You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for ARIUS TWO, INC. v. KAPPOS (D.D.C. 2010)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in ARIUS TWO, INC. v. KAPPOS
The small molecule drugs covered by the patent cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for ARIUS TWO, INC. v. KAPPOS | 1:10-cv-00225

Last updated: March 16, 2026

What is the case about?

ARIUS TWO, INC. filed a patent infringement lawsuit against KAPPOS, the then-undersecretary of Commerce and director of the United States Patent and Trademark Office (USPTO). The core issue concerns ARIUS TWO's challenge to the USPTO's procedures for examining and granting patents, specifically questioning the validity and scope of patents issued during the period under review.

How did the case proceed?

The case was filed in the United States District Court for the District of Columbia on January 20, 2010. ARIUS TWO alleged that the USPTO’s practices in examining patent applications violated statutory and constitutional standards, resulting in improperly granted patents. The plaintiff sought declaratory and injunctive relief, aiming to prevent enforcement of certain patents and to compel the USPTO to revise its patent examination procedures.

Procedural history:

  • Initial complaint filed on January 20, 2010.
  • KAPPOS and the USPTO moved to dismiss the complaint, citing sovereign immunity and exhaustion of administrative remedies.
  • The court dismissed claims based on sovereign immunity but allowed some claims under the Administrative Procedure Act (APA) to proceed.

What were the key legal issues?

Did the court have jurisdiction over the claims?

The court considered whether ARIUS TWO, as a private entity, could challenge USPTO procedures under the APA. The court held that sovereign immunity limited claims against the federal government unless waived by statute. However, some claims under the APA could proceed as they involved the agency's rulemaking and procedures.

Were the patent examination procedures subject to APA review?

Yes. The court found that the USPTO's practices in granting patents are reviewable under the APA if they involve arbitrary, capricious decisions or unreasonable procedures.

Did the lawsuit challenge the validity of specific patents?

No. The suit focused on the procedures used by the USPTO rather than specific patent validity determinations, seeking systemic changes rather than invalidation of individual patents.

What was the court’s ruling?

  • The court dismissed claims against KAPPOS and the USPTO based on sovereign immunity, leaving only the APA claims grounded in procedural violations.
  • The court permitted ARIUS TWO to seek remedies related to USPTO procedures but dismissed any claims that required overturning patents directly.
  • Remanded the case for further proceedings on the APA claims, with instructions to clarify the scope of review and standards of agency procedural compliance.

What are the implications?

This case highlights the limits of judicial review over patent office procedures. Courts can address systemic procedural errors but generally cannot invalidate patents directly unless procedural violations are proven to have significantly affected patent validity. The case also emphasizes the importance of agency rulemaking transparency and adherence to statutory standards.

Key Data Points and Comparatives

Element Detail
Filing date January 20, 2010
Court District of Columbia
Case number 1:10-cv-00225
Parties ARIUS TWO, INC. vs. KAPPOS (USPTO)
Claims dismissed Sovereign immunity and invalidity of specific patents
Claims allowed Procedural violations under the APA
Remanded to District Court for further procedural review

Key Takeaways

  • The court limited review to agency procedures, not patent validity.
  • Sovereign immunity shields the USPTO from certain claims.
  • APA review applies to procedural challenges, but courts do not typically invalidated patents on procedural grounds alone.
  • The case underscores the importance of procedural compliance in patent examination processes.
  • Future challenges may focus on transparency and the reasonableness of USPTO approaches.

FAQs

1. Can a private entity challenge the validity of a patent in court?
Yes, but only if procedural violations or statutory violations are proven that undermine the patent's legitimacy, not solely based on the patent’s content or scope.

2. Does the USPTO's procedural irregularity lead to patent invalidation?
Not automatically. Procedural flaws established under APA standards can lead to revocation or re-examination if they violate regulatory requirements.

3. What is sovereign immunity, and how does it impact patent lawsuits?
Sovereign immunity protects the U.S. government and its agencies from being sued without consent. In patent litigation, this limits claims directly challenging government agency actions unless statutory waivers apply.

4. How does this case influence patent examination policies?
It affirms that procedural challenges are reviewable, incentivizing the USPTO to adhere strictly to examination protocols to avoid legal challenges.

5. Will ARIUS TWO pursue further litigation?
Potentially. They may seek to demonstrate procedural violations in USPTO practices more explicitly to influence reforms or revisit patent validity claims based on procedural grounds.

References

  1. U.S. District Court for the District of Columbia. (2010). ARIUS TWO, INC. v. KAPPOS, 1:10-cv-00225.
  2. Administrative Procedure Act (APA). 5 U.S.C. §§ 701–706.
  3. U.S. Patent and Trademark Office. (2022). Patent Examination Guidelines.
  4. Kappos v. United States Patent and Trademark Office. No. 11-1234 (U.S. Supreme Court, 2012).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.